We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-0.68%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.76B
AUM Growth
-$304M
Cap. Flow
+$23.1M
Cap. Flow %
0.49%
Top 10 Hldgs %
26.26%
Holding
167
New
11
Increased
69
Reduced
16
Closed
14

Top Buys

Rank Stock Value
1
BAX icon
Baxter International
BAX
+$35.6M
2
WRBY icon
Warby Parker
WRBY
+$35M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$30.4M
4
IMRX icon
Immuneering
IMRX
+$29.3M
5
ABOS icon
Acumen Pharmaceuticals
ABOS
+$26.3M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$68.6M
2
ARDX icon
Ardelyx
ARDX
+$39.8M
3
BIIB icon
Biogen
BIIB
+$39.3M
4
BSX icon
Boston Scientific
BSX
+$34.2M
5
PPD
PPD, Inc. Common Stock
PPD
+$31.1M

Sector Composition

Rank Sector Weight
1 Healthcare 93.24%
2 Consumer Staples 1.58%
3 Industrials 0.82%
4 Financials 0.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOCL
126
EDAP TMS S.A.
FOCL
$228M
$4.86M 0.1%
760,900
– –
ATAI icon
127
AtaiBeckley Inc
ATAI
$2.68B
$4.7M 0.1%
317,628
+2,600
+0.8% +$42.3K
GRTX
128
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$4.6M 0.1%
568,252
– –
TPST icon
129
Tempest Therapeutics
TPST
$16.6M
$4.49M 0.09%
23,859
– –
EPIX
130
DELISTED
ESSA Pharma
EPIX
$4.06M 0.09%
508,044
+5,009
+1% +$79.6K
TLPH icon
131
Talphera
TLPH
$73.2M
$3.9M 0.08%
190,970
+1,532
+0.8% +$35.1K
INNV icon
132
InnovAge Holding
INNV
$1.48B
$3.47M 0.07%
525,000
-377,500
-42% -$5.84M
ELVN icon
133
Enliven Therapeutics
ELVN
$4.35B
$3.38M 0.07%
+207,276
New +$4.31M
BLSA
134
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$3.08M 0.06%
309,000
– –
BCEL
135
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$2.87M 0.06%
459,830
– –
NUVB icon
136
Nuvation Bio
NUVB
$2.32B
$2.35M 0.05%
236,609
-4,876
-2% -$44.2K
PSTX
137
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$2.11M 0.04%
289,754
– –
PRDS
138
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$2.08M 0.04%
209,332
– –
EUCRU
139
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
$2.05M 0.04%
206,000
– –
TMPMU
140
DELISTED
Turmeric Acquisition Corp. Unit
TMPMU
$2.05M 0.04%
206,000
– –
PHICU
141
DELISTED
Population Health Investment Co., Inc. Unit
PHICU
$2.01M 0.04%
201,044
– –
JYAC
142
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$2.01M 0.04%
206,200
– –
MLTX icon
143
MoonLake Immunotherapeutics
MLTX
$1.47B
$1.54M 0.03%
154,500
– –
APLS
144
DELISTED
Apellis Pharmaceuticals
APLS
$872K 0.02%
+26,458
New +$1.49M
NUVB.WS
145
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$343K 0.01%
134,028
– –
ACAD icon
146
Acadia Pharmaceuticals
ACAD
$5.06B
– –
-1,000,000
Closed -$24.4M
ADPT icon
147
Adaptive Biotechnologies
ADPT
$4.05B
– –
-650,000
Closed -$26.6M
APLS
148
CALL
DELISTED
Apellis Pharmaceuticals
APLS
– –
-157,900
Closed -$9.98M
ARDX icon
149
Ardelyx
ARDX
$997M
– –
-5,248,829
Closed -$39.8M
BIIB icon
150
Biogen
BIIB
$30.6B
– –
-113,500
Closed -$39.3M
3 4 5
6
7

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Rock Springs Capital Management held 167 positions worth $4.76B, down 6% from $5.06B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Rock Springs Capital Management's Q3 2021 filing shows 11 new, 69 increased, 16 reduced and 14 closed positions. Its largest new stake was Baxter International: 450,000 shares worth $36.2M. The largest sale was BeOne Medicines Ltd, an estimated $68.6M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q3 2021 buy was Baxter International: 450,000 shares worth $36.2M.
  • Rock Springs Capital Management added most to Ultragenyx Pharmaceutical in Q3 2021, an estimated $30.4M increase.
  • Rock Springs Capital Management's biggest Q3 2021 reduction was Prothena Corp, cutting an estimated $14.9M.
  • Rock Springs Capital Management fully exited BeOne Medicines Ltd in Q3 2021, selling an estimated $68.6M.
  • Rock Springs Capital Management's ten largest holdings make up 26% of its $4.76B portfolio in Q3 2021.
  • Rock Springs Capital Management opened 11 new positions and closed 14 in Q3 2021.
  • Rock Springs Capital Management's portfolio value fell 6% quarter-over-quarter to $4.76B.

Based on Rock Springs Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.